Several other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Johnson & Johnson from a buy rating to a hold rating in a research note on Tuesday, September 20th. Credit Suisse Group AG reissued a neutral rating and issued a $123.00 target price on shares of Johnson & Johnson in a research note on Monday, September 19th. Jefferies Group reduced their target price on shares of Johnson & Johnson from $119.00 to $115.00 and set a hold rating on the stock in a research note on Tuesday, September 13th. Leerink Swann reissued a buy rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Finally, BTIG Research reissued a neutral rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson presently has a consensus rating of Hold and a consensus price target of $120.19.
Johnson & Johnson (NYSE:JNJ) opened at 117.78 on Wednesday. The company’s 50-day moving average is $119.81 and its 200-day moving average is $116.47. The stock has a market capitalization of $322.23 billion, a PE ratio of 21.95 and a beta of 0.61. Johnson & Johnson has a 12 month low of $91.76 and a 12 month high of $126.07.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. The company had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Equities research analysts forecast that Johnson & Johnson will post $6.69 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were paid a dividend of $0.80 per share. The ex-dividend date was Friday, August 19th. This represents a $3.20 annualized dividend and a yield of 2.72%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
A number of large investors have recently made changes to their positions in JNJ. Americafirst Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $101,000. Tuttle Tactical Management LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $103,000. Lenox Wealth Management Inc. raised its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. raised its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. bought a new position in Johnson & Johnson during the second quarter valued at approximately $127,000. 65.32% of the stock is currently owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.